HOPHF (Hemogenyx Pharmaceuticals) Total Payout Yield %: -11.17 (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOPHF Hemogenyx Pharmaceuticals PLC HOPHF
31 GF Score
Price $2.33
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals Total Payout Yield %?

Hemogenyx Pharmaceuticals HOPHF 31 Total Payout Yield % is -11.17 as of Jul. 27, 2026. GuruFocus rates HOPHF with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Hemogenyx Pharmaceuticals's current Total Payout Yield % is -11.17%.


Hemogenyx Pharmaceuticals Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Hemogenyx Pharmaceuticals Total Payout Yield % Related Terms


Hemogenyx Pharmaceuticals Total Payout Yield % Historical Data

* Premium members only.

The historical data trend for Hemogenyx Pharmaceuticals's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemogenyx Pharmaceuticals Total Payout Yield % Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -13.70 -107.98 -52.52

Hemogenyx Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.30 -14.98 -32.12 -96.13 -66.67

HOPHF vs VRTX, REGN, RVMD: Total Payout Yield % Comparison

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemogenyx Pharmaceuticals Total Payout Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's Total Payout Yield % falls into.


HOPHF
31GF Score
Hemogenyx Pharmaceuticals PLC HOPHF
Total Payout Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Hemogenyx Pharmaceuticals's Total Payout Yield % for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 7.392 + 0) / 14.07553
=-52.52%

Hemogenyx Pharmaceuticals's annualized Total Payout Yield % for the quarter that ended in Dec. 2025 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 4.692 + 0) * 2 / 14.07553
=-66.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Yield % →
What does a Total Payout Yield % of -11.17 mean?
Hemogenyx Pharmaceuticals (HOPHF) has a Total Payout Yield % of -11.17 as of Jul. 27, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Hemogenyx Pharmaceuticals and its competitors.
Is Hemogenyx Pharmaceuticals' Total Payout Yield % too high?
Hemogenyx Pharmaceuticals' current Total Payout Yield % is -11.17. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' Total Payout Yield % compare to VRTX and REGN?
Hemogenyx Pharmaceuticals' Total Payout Yield % of -11.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Biotechnology company?
A good Total Payout Yield % depends on the Biotechnology industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Hemogenyx Pharmaceuticals and its competitors. Hemogenyx Pharmaceuticals's current Total Payout Yield % is -11.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (HOPHF) has a current Total Payout Yield % of -11.17. The current Total Payout Yield % is -11.17. Hemogenyx Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (HOPHF), the current Total Payout Yield % is -11.17 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemogenyx Pharmaceuticals Business Description

Other Exchanges HEMO:UK
Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
31GF Score

Get the complete analysis for HOPHF

Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price